Today's in-space tools weren't built for tomorrow's therapies
In-space biology has proven what microgravity can do. Turning that into products needs the automation, scale and analytics of a modern cell-manufacturing suite.
Present capabilityNot good enough
- Stage
- Fundamental, discovery
- Scalability
- Not scalable
- Process
- Manual, limited automation
- Measurement
- Subjective, prone to human error
- Environment
- Confounding variables of microgravity and radiation
Current demandState of the art
- Stage
- Translational, clinical
- Scalability
- Scalable platform
- Process
- Automated, reproducible
- Quality
- Standardized analytics
- Performance
- Higher efficiency and yield, optimized for space
Where LEO Biosciences differs from other in-space biomanufacturing offerings
Proven on Earth, re-engineered for microgravity
Commercial terrestrial technologies adapted for orbit, so results translate to the ground.
Designed for clinical cell manufacturing
Built from day one for FDA-compliant clinical cell manufacturing.
Patents filed, more pending
Multiple IP partners and patents filed, with provisional patents converted, patent-pending drug production and multi-phase fluid management IP.
2027 demonstrations locked
- ISS National Laboratory agreement for the first validation flight
- Technical evaluation of biomanufacturing technologies on Dream Chaser free-flyer mission
- Evaluation of robot-compatible operations on ISS
- Additional contracts pending for flight projects in 2027 and 2028
One platform, many customers
Serves biopharma, regenerative medicine, cancer therapeutics and commercial LEO destination hardware customers.
Executed by spaceflight veterans
More than 100 years of combined spaceflight heritage across engineering and biology.
More capabilities, at lower cost, in one integrated system
Existing in-space offerings each cover part of this list. OSPRI is designed to deliver all eight.